Enantone 1-Month DPS 3.75 mg/Enantone 3-Month DPS 11.25 mg/Enantone 6-Month DPS 30 mg Indications/Uses

Enantone 1-Month DPS 3.75 mg: Endometriosis; Decrease of myoma volume and/or amelioration of symptoms in uterine myoma with hypermenorrhea, hypogastralgia, low back pain, anemia, etc; Premenopausal breast cancer; Prostate cancer; Central precocious puberty.
Precautions for Indications: Uterine myoma: It should be noted that the treatment of uterine myoma with ENANTONE is not a radical treatment. Therefore, as a rule, this drug should be used as a means of providing conservative treatment until operation on patients requiring operation or providing premenopausal conservative treatment. For hypogastralgia and low back pain, the effect of this drug is not observed at the early period after administration. During such a period, therefore, appropriate symptomatic treatment should be given.
Premenopausal breast cancer: When starting treatment with ENANTONE, absence/presence of hormone receptor expression should be confirmed as a rule. When hormone receptor expression is confirmed to be negative, ENANTONE should not be used.
Enantone 3-Month DPS 11.25 mg: In male: Prostate cancer and its secondarisms.
In female: Genital and extragenital endometriosis (Phase I-IV); Breast cancer in pre and peri-menopausal women, where a hormone treatment is indicated; Uterine fibroids.
In children: Treatment of central precocious puberty (before age 9 in girls and before 10 years in boys).
Enantone 6-Month DPS 30 mg: ENANTONE 6 MONTH DPS is applied in male adults for treatment of the advanced hormone-dependent prostate carcinoma.
For the treatment of locally advanced hormone dependent prostate cancer; during and following radiation therapy.
For the treatment of localized hormone dependent prostate cancer in patients with intermediate- and high risk in combination with radiation therapy.